Pharmaceutical Technology

MARCH 16, 2023

Talem Therapeutics, a subsidiary of Immunoprecise Antibodies, has entered a multi-target artificial intelligence (AI)-driven antibody discovery collaboration with Libera Bio. The MPN Technology provides an elegant way for delivering antibodies inside tumour cells.

Antibody 262

Antibody In-Vivo Pharma Companies Protein 262

Pharmaceutical Technology

APRIL 18, 2024

Discover how Vir Biotechnology's patented multispecific antibodies target distinct Zika virus epitopes, neutralizing ZIKV infection. Explore the innovative potential for prophylaxis and treatment in this groundbreaking patent.

Antibody 130

Antibody 130

Pharmaceutical Technology

APRIL 23, 2024

UCB SA patent for IL-17A and IL-17F antibody molecules with expression vectors and host cell methods. Discover the innovative approach to efficient nucleic acid expression.

Antibody 130

Antibody 130

Pharmaceutical Technology

AUGUST 24, 2023

Japan has granted a new drug substance patent for BioArctic’s monoclonal antibody (mAb), BAN0805, to treat Parkinson’s disease.

Antibody 245

Antibody Drugs 245

Pharmaceutical Technology

APRIL 22, 2024

Discover a broader repertoire of antibodies with a recently granted patent. Enhance immunoglobulin diversity with AbCellera's patented method for isolating B cells from genetically modified mice.

Genetics 130

Genetics Antibody Production 130

Pharmaceutical Technology

FEBRUARY 15, 2023

In the last three years alone, there have been over 633,000 patents filed and granted in the pharmaceutical industry, according to GlobalData’s report on Immuno-oncology: Leading companies in cancer monoclonal antibody therapy. Immatics is one of the most important players concerning innovation surrounding cancer monoclonal antibody therapy.

Antibody 261

Antibody Immune Response Protein Development 261

Pharmaceutical Technology

APRIL 22, 2024

Discover the groundbreaking patent by OSE Immunotherapeutics SA for humanized monoclonal antibodies targeting CD127, offering innovative solutions for inhibiting inflammation and treating autoimmune, allergic, and viral diseases.

Antibody 130

Antibody 130

Pharmaceutical Technology

APRIL 10, 2024

Discover the groundbreaking patent by Kyowa Kirin Co Ltd for a monoclonal antibody targeting CCR1, inhibiting its activation by CCL15. Explore the therapeutic and diagnostic potential for CCR1-related diseases.

Antibody 130

Antibody 130

Pharmaceutical Technology

APRIL 23, 2024

Learn about modified antibodies and potential treatments in this groundbreaking publication. Discover Bristol-Myers Squibb's innovative patent for a pharmaceutical composition targeting human CD40 activity.

Antibody 130

Antibody 130

Pharmaceutical Technology

APRIL 9, 2024

The grant will support the preclinical development of the antibody acquired by Basilea from Spexis in January.

Antibody 130

Antibody Development 130

Pharmaceutical Technology

APRIL 15, 2024

Discover Genzyme Corp's innovative method for detecting anti-drug antibodies in human body fluids. Learn how their patented process reduces interference in drug assays effectively.

Antibody 130

Antibody Drugs 130

Pharmaceutical Technology

APRIL 18, 2024

Explore the innovative fusion polypeptide with IL-2 and antibody Fc region, revolutionizing T cell activity modulation. Discover Cue Biopharma's groundbreaking patent for variant immunomodulatory polypeptides and fusion polypeptides, including T-cell modulatory multimeric polypeptides.

Antibody 130

Antibody 130

Pharmaceutical Technology

MARCH 28, 2024

Revolutionize cancer treatment with OSE Immunotherapeutics' patented anti-SIRPa antibodies targeting human SIRPa for enhanced T cell response and antigen presentation. Discover a comprehensive approach to treating various cancers with innovative combination therapies.

Antibody 130

Antibody 130

Drug Discovery World

MAY 1, 2024

DDW’s Megan Thomas speaks to industry experts and thought leaders about the potential for therapeutic antibodies in 2024. Many of the best-selling drugs in 2023 were monoclonal antibody (mAB) therapies, including Keytruda (pembrolizumab), Humira (adalimumab), and Dupixent (dupilumab) 1.

Antibody 59

Antibody FDA Approval Drugs Development 59

Pharmaceutical Technology

OCTOBER 21, 2022

AbbVie has announced the acquisition of UK-based biotechnology firm DJS Antibodies for nearly $255m in cash at closing. DJS focuses on the discovery and development of antibody therapies that act on difficult-to-drug disease-causing proteins, such as G protein-coupled receptors (GPCRs).

Antibody 217

Antibody Protein Licensing Licensing 217

Pharmaceutical Technology

APRIL 1, 2024

Treat systemic lupus erythematosus effectively with UCB SA's patented method using a specific antibody to CD154. Significant improvements in SLE indices and outcomes. Explore the potential of this innovative treatment now!

Antibody 130

Antibody 130

Pharmaceutical Technology

APRIL 15, 2024

Discover a groundbreaking method to treat renal disorders with AVEO Pharmaceuticals Inc's patented anti-GDF15 antibody. Learn how this innovative approach targets hyperuricemia and CKD for improved renal function.

Antibody 130

Antibody 130

Pharmaceutical Technology

JULY 21, 2022

AstraZeneca has signed a deal with the Federal Office of Public Health (FOPH) of Switzerland to deliver over 1,200 doses of antibody therapy, tixagevimab and cilgavimab combination (AZD7442), for Covid-19 prevention and treatment. In June 2020, these antibodies, discovered at Vanderbilt University Medical Center, were licensed to AstraZeneca.

Antibody 264

Antibody Compliance Clinical Trials Clinical Trials 264

Pharmaceutical Technology

FEBRUARY 22, 2024

The company’s monoclonal antibody therapy, IO-202, has received its second orphan drug designation as a treatment for a blood cancer, CMML.

Antibody 130

Antibody Drugs 130

Pharmaceutical Technology

MARCH 26, 2024

Discover Pfizer's innovative patent for multi-drug Antibody Drug Conjugates and Linking Assembly Units, enabling precise and effective drug delivery. Explore the cutting-edge technology behind site-specific construction and versatile drug linking options.

Antibody 130

Antibody Drug Delivery Drugs 130

Pharmaceutical Technology

DECEMBER 22, 2023

Ono has signed an agreement with EVQLV to utilise its AI-powered antibody design engine for the development of new antibody drugs.

Antibody 130

Antibody Development Engineer Drugs 130

Pharmaceutical Technology

MARCH 26, 2024

Discover Genmab AS's innovative patent for treating DLBCL with a bispecific antibody and R-CHOP regimen. Learn about specific dosages and administration schedules for improved patient outcomes.

Antibody 130

Antibody 130

Pharmaceutical Technology

FEBRUARY 22, 2024

Ono Pharmaceutical has partnered with EME to advance the drug discovery of VHH antibodies to develop new therapeutic agents.

Antibody 130

Antibody Drugs Development 130

Pharmaceutical Technology

JANUARY 9, 2023

Eisai and Biogen have received approval for their antibody Leqembi (lecanemab-irmb) , 100mg/mL injection for intravenous use, from the US Food and Drug Administration (FDA) under the Accelerated Approval Pathway to treat Alzheimer’s disease (AD). The regulatory approval is based on the data obtained from the Phase II trial.

FDA Approval 246

FDA Approval Antibody Clinical Trials Clinical Trials 246

Pharmaceutical Technology

MAY 8, 2023

In the last three years alone, there have been over 633,000 patents filed and granted in the pharmaceutical industry, according to GlobalData’s report on Innovation in Pharmaceuticals: Anti-influenza antibody compositions. However, not all innovations are equal and nor do they follow a constant upward trend.

Antibody 246

Antibody Vaccination Vaccine Dermatology 246

BioSpace

APRIL 12, 2024

This week’s American Association for Cancer Research annual meeting drove home the importance of antibody-drug conjugates as an emerging class of potential anti-cancer therapeutics.

Antibody 118

Antibody Drugs Research 118

Pharmaceutical Technology

APRIL 15, 2024

Discover how Atrium Health's groundbreaking patent revolutionizes cancer treatment with targeted antibodies and cytotoxic cells, enhancing immune response and improving patient outcomes.

Antibody 130

Antibody Immune Response Engineer 130

Pharmaceutical Technology

DECEMBER 22, 2023

Discover a groundbreaking method for preparing conditionally active antibodies. This recently granted patent covers evolving DNA to increase acidic amino acid residues, selecting mutants, and assessing activity under specific conditions. Explore the potential of this innovative approach.

Antibody 100

Antibody DNA 100

Pharmaceutical Technology

MAY 24, 2023

HBM’s wholly owned subsidiary Nona Biosciences has entered an agreement with OPKO Health’s ModeX Therapeutics for the discovery of antibodies. ModeX Therapeutics will gain access to the fully human Harbour Mice platforms of Nona Bioscience for integration into its MSTAR platform to expedite the monoclonal antibodies’ discovery.

Antibody 147

Antibody Clinical Development Development Research 147

Pharmaceutical Technology

NOVEMBER 28, 2023

Boehringer Ingelheim has entered an agreement with IBM to leverage the latter’s foundation model technologies for antibody discovery.

Antibody 130

Antibody 130

pharmaphorum

MARCH 25, 2024

FDA has turned down a pair of marketing applications for Regeneron’s CD20xCD3 bispecific antibody odronextamab to treat two common forms of non-Hodgkin lymphoma

Antibody 108

Antibody Marketing 108

Drug Discovery World

APRIL 29, 2024

Join DDW for this free event ‘ Where is the opportunity in the therapeutic antibody market? ’, which is co-sponsored by Bio-Rad and Benchling. Dr Milind Nigam will discuss the role of software in accelerating the pace of discovery of antibody therapeutics. What effect has antibody engineering had on drug discovery and development?

Antibody 52

Antibody Marketing Gene Therapy Engineer 52

Bio Pharma Dive

APRIL 21, 2023

A decision by the Supreme Court could have far-reaching effects on the lucrative market for antibody drugs, spurring responses from many of the industry’s top companies.

Antibody 183

Antibody Marketing Drugs 183

Pharmaceutical Technology

FEBRUARY 19, 2024

An FDA approval in late 2024 would make it the first TROP2-directed therapy for NSCLC antibody drug conjugate patients.

Antibody 130

Antibody FDA Approval Drugs 130

Pharmaceutical Technology

JANUARY 23, 2024

Calluna has four monoclonal antibody candidates in the pipeline under development for inflammatory and fibrotic diseases.

Antibody 130

Antibody Development 130

Pharmaceutical Technology

DECEMBER 11, 2023

Nona Biosciences has entered a partnership deal with biopharmaceutical company Evive Biotech to discover antibodies.

Antibody 130

Antibody 130

Bio Pharma Dive

JUNE 16, 2021

The biotech said it will seek an expanded FDA clearance after results from the RECOVERY trial showed its antibody can lower mortality among certain hospitalized COVID-19 patients.

Antibody 319

Antibody Trials 319